HomeNewsPar pharmaceuticals

Par Pharmaceuticals

Jump to

New launches to drive earnings growth in FY18 & FY19: Glenmark

The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said.
Use intermittent dips to buy; like Yes Bank: Prabhudas Lilladher

In an interview with CNBC-TV18, he said that Yes Bank and IndusInd Bank are his top picks in the banking space and advised to buy Yes Bank on dips.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Par Pharmaceuticals

New launches to drive earnings growth in FY18 & FY19: Glenmark

Use intermittent dips to buy; like Yes Bank: Prabhudas Lilladher